Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report released on Wednesday morning, Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock. A number of other brokerages have also recently weighed in on ESPR. Bank of America cut Esperion Therapeutics from […]
More Stories
PepsiCo (NASDAQ:PEP) PT Raised to $185.00
PepsiCo (NASDAQ:PEP – Free Report) had its target price raised by JPMorgan Chase & Co. from $182.00 to $185.00 in...
PepsiCo (NASDAQ:PEP) PT Raised to $185.00
PepsiCo (NASDAQ:PEP – Free Report) had its target price raised by JPMorgan Chase & Co. from $182.00 to $185.00 in...
PepsiCo (NASDAQ:PEP) PT Raised to $185.00
PepsiCo (NASDAQ:PEP – Free Report) had its target price raised by JPMorgan Chase & Co. from $182.00 to $185.00 in...
The Real State of the U.S. Economy: Unemployment Figures Twice as High Under Biden-Harris Administration
By Stephen Zogopoulos, USNN World News As the Biden-Harris administration continues to tout economic recovery and low unemployment rates, a...
The Real State of the U.S. Economy: Unemployment Figures Twice as High Under Biden-Harris Administration
By Stephen Zogopoulos, USNN World News As the Biden-Harris administration continues to tout economic recovery and low unemployment rates, a...
The Real State of the U.S. Economy: Unemployment Figures Twice as High Under Biden-Harris Administration
By Stephen Zogopoulos, USNN World News As the Biden-Harris administration continues to tout economic recovery and low unemployment rates, a...